Generali Asset Management SPA SGR Increases Stake in Edwards Lifesciences Corporation $EW

Key Points

• Generali Asset Management SPA SGR increased its stake in Edwards Lifesciences Corporation by 10.5% during the second quarter, owning a total of 39,121 shares valued at approximately $3,060,000.
• Recent trading activity includes insider sales, with VP Daniel J. Lippis selling 4,114 shares and another insider, Larry L. Wood, selling 8,950 shares, both resulting in notable decreases in their positions.
• Analysts show a mixed outlook, with ratings fluctuating from "Strong Buy" to "Sell," and a consensus price target of $87.06 for Edwards Lifesciences shares.

Generali Asset Management SPA SGR lifted its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 10.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 39,121 shares of the medical research company's stock after purchasing an additional 3,732 shares during the quarter. Generali Asset Management SPA SGR's holdings in Edwards Lifesciences were worth $3,060,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences in the 1st quarter valued at approximately $26,000. SouthState Corp purchased a new position in shares of Edwards Lifesciences in the 1st quarter valued at approximately $27,000. Rossby Financial LCC purchased a new position in shares of Edwards Lifesciences in the 1st quarter valued at approximately $29,000. Costello Asset Management INC purchased a new position in shares of Edwards Lifesciences in the 1st quarter valued at approximately $29,000. Finally, Global X Japan Co. Ltd. raised its position in shares of Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after purchasing an additional 216 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on EW shares. Truist Financial increased their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a report on Friday, July 25th. BTIG Research upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target on the stock in a report on Tuesday, July 29th. Oppenheimer downgraded shares of Edwards Lifesciences from an "outperform" rating to a "market perform" rating in a report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a report on Friday, July 25th. Finally, JPMorgan Chase & Co. increased their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $87.06.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $72.66 on Friday. The stock has a market capitalization of $42.66 billion, a price-to-earnings ratio of 10.45, a PEG ratio of 3.50 and a beta of 1.05. Edwards Lifesciences Corporation has a 12 month low of $64.89 and a 12 month high of $83.00. The firm's 50 day simple moving average is $77.61 and its 200-day simple moving average is $76.14. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business's revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.